Member Info for lofas

…and that shortlist if I’m not mistaken is from 1000s of bio companies out there.

Nice feedback from Krafty.

Yes agreed with all the points you raised. We all agree the LD would like to shout at the earliest opportunity assuming Modi does what is written on the tin. I like others is willing to wait patiently to this moment to arrive, equally, if big pharma wants to jump the queue and put Xs on the table, well it want upset if they got in update before.

No comment.

Update or X £B on table table… I will take the X.

Based on review of the safety data from Cohort 3, dose escalation to Cohort 4 has been approved by the Safety Review Board and the first patient has been dosed.

Data is included up until the date of the poster acceptance by ASCO and concludes that Modi-1 is well tolerated and that the early efficacy data from the monotherapy arms of the trial remain encouraging.

No additional news with the Content of video, however one can assume that the release of video affirm/indicate that progress is in line with expectations and outcome is encouraging, otherwise continuous funding of the trial would be questionable…aimo and good luck to all.

Do we know of any other immunotherapy product that can do what modi-1delivered ? Albeit , may not be statistically significant yet. 50% reduction in one patient and keeping prognosis unchanged for others. Remarkable imho, as so is the current share price.

Must be with the knowledge and consent of scan. Can’t imagine this publication otherwise.

Had a dream it got delisted.

It’s AIM culture.

Hi JB1, interesting, so the run up to end of July will be closely watched. Thanks.

45p ? Please help a friend to understand the logic behind. Thanks

Based on the following “ We also know that they were screening for cohort 4 so presumably must have received approval from the Safety Review Board to increase the dose.”. I assume that SC git the green light to progress.

Berms, regarding cohort 3, This is great in particular the mix of scan’s tools and Keytruda. We may get update sometime in May? Also the green light to recruit for Cohort 4 is very encouraging.

Especially as Modi platform can provide another life line to Merck’s Keytruda which increases year on year and revenue in 22 was over $20Bn USD.

Prior to Merck’s approach , Prometheus Biosciences was valued ~$6Bn if I’m not mistaken? Adding another 65% is a small multiple. Scan should be on Mercks radar…time will tell.

If indeed the prime purpose is to stand by their poster, then any discussion we be centred around published data. Unpublished data will require RNS. Really puzzling what could be the motives of LD is not taking the podium.

Vulpes have taken a different approach: This is what Scancell would be worth IF SUCCESSFUL.
To come up with this approach is imho an indication that they have a good degree of confidence (>50%) of the outcome…speculative..maybe but has to be a very good reason behind the publication of their note.